Search

Vaccine R&D Factory

VACCINE R&D FACTORY

Invest with us in New S-Pharma mRNA vaccine and Smart medicines R&D factory and become Shareholder
- Pre IPO Investment -

S-Pharma London U.K. - Investment in Biopharmaceutical  Research and development (R&D)  Company  and activities that focus on the innovation of new products.    
S-Pharma R&D for mRNA vaccine and smart medicines. Discovering, developing and providing different branche of vaccines and medicines. 
Pre IPO Investment
Very limited share offering

A New Approach to Medicine

  • mRNA medicines take advantage of normal biological processes to express proteins and create a desired therapeutic effect. 
  • This enables the potential treatment of a broad spectrum of diseases, many of which cannot be addressed with current technologies.

Therapeutic areas:

  • Infectious Diseases
  • Immuno-Oncology
  • Cardiovascular Diseases
  • Autoimmune Diseases
  • Rare Diseases

Project info:

  • The development is due to complete in Q4 2022/Q2 2023
Brand new Biopharmaceutical R&D factory with vaccine and medicines factory. 

  • Type of business: Biopharmaceutical R&D (research & development) factory for mRNA vaccine and smart medicines. 
  • The development is due to complete in  Q4 2022/Q2 2023    
  • Location of Investment: European Union (EU) 
  • Pre IPO Investment
  • Very limited share offering
  • Full Investment (Capital cost): 640.000.000 € based on one large R&D Factory for Vaccine and medicines.
  • Holdings: Total of 640 Share at 1.000.000 €. 
  • Min. investment 10.000.000 € for 10 share and 10 Voting Rights 
  • Max. Investment 288..000.000 € for 288 Share (45%  Ownership)
  • One Share are One voting Rights. 
  • Vaccine factory stocks give additional income, or you can sell it at a higher price per share and earn from it as well. 
  • Our project report also maintains that will grow by over next five years with Up to 24% return pro year. 
  • International management team with record of success.
Ownership of shares (until now): 

  • S-Pharma U.K. own 160 share (25% ownership) 
  • Live Insurance Company U.K (data known to management) 54 share
  • Pharmaceutical Company (data known to management)  30 share
  • Pharmaceutical Company 2 (data known to management)  10 share
  • Investment funds (two Investment fund from USA and EU) (data known to management) 40 share
  • Investment Bank  (data known to management)  30 share
  • Private Investor (data known to management) 28 share (Investor from: Suisse, UK, USA, Russia, Germany, UAE, SA, China, Italy, Bahrain, Poland, Kuwait, Croatia, Spain, Israel, Netherland, Sweden, Norvege, Danemark and Island
  • Reserved 5 share for new custormer (08/31/2021)
  • Free for investors: 288 share
  • Every Investor have "Memorandum and Articles of Association" and shareholder certify
  • One Share are One voting Rights
  • Project number: 888 048
Vaccine R&D Factory

In cooperation with S-Pharma London U.K.
Project documentation for investors:

  • Complete project documentation of  Biopharmaceutical R&D (research & development) factory for mRNA vaccine and smart medicines. 
  • Financial Analysis 
  • Feasibility 
  • Technical calculation 
  • Designing 
  • Supervision 
  • Installation 
  • Miscellaneous 
  • Support Structure 
  • Specification 2.000,000 € for complete project documentation for investors
  • If you buy a share the money for project documentation is returned

Payment Information and method:

Please contact us for more information
VACCINE R&D FACTORY

Vaccine R&D Factory

  • Vaccines are one of the greatest public health success stories in history. 
  • S-Pharma and its legacy companies and our partners have been working to discover and develop vaccines. Our vaccines have helped prevent a number of diseases, including ones never thought preventable. Today, we remain dedicated to the complex business of researching and producing vaccines. 
  • Now S-Pharma and our partners have been working to discover and develop coronavirus vaccines.
  • BCG Vaccine: up to 200 mill/Year 
  • VARICELLA VACCINE: up to 200 mill/Year 
  • MMR VACCINE: up to 200 mill/Year 
  • DTP VACCINE: up to 200 mill/Year 
  • INFLUENCA VACCINE: up to 200 mill/Year 
  • PNEUMO VACCINE: up to 200 mill/Year 
  • ROTA VACCINE: up to 200 mill/Year 
  • EVAC (Ebola Vaccine): up to 200 mill/Year 
  • CORONAVIRUS VACCINE (COVID19)  : up to 900 mill/Year 
MEDICINES: Consumer & Prescription medicine 
  • CHC – Consumer Healthcare 
  • Rx – Prescription medicine